The two peptide lantibiotic lacticin 3147 acts synergistically with polymyxin to inhibit Gram negative bacteria

BMC Microbiology

Volumn 13, Issue 1, 2013, Pages

  Draper, Lorraine A ^a   Cotter, Paul D ^b,c   Hill, Colin ^a,b   Ross, R Paul ^b,c  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c TEAGASC FOOD RESEARCH CENTRE   (Ireland)

Author keywords

Antimicrobial; Bacteriocin; Lacticin 3147; Lantibiotic; Polymyxin; Synergy

Indexed keywords

BACITRACIN; CEFACLOR; CEFOPERAZONE; CEFOTAXIME; CEFRADINE; CEFTAZIDIME; COLISTIN; FUSIDIC ACID; IMIPENEM; LACTICIN 3147; LANTIBIOTIC; NOVOBIOCIN; OXACILLIN; PENICILLIN G; POLYMYXIN B; TEICOPLANIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIOCIN; LACTICIN 481; POLYMYXIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACILLUS CEREUS; BACTERIAL STRAIN; CRONOBACTER; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; GROWTH INHIBITION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SALMONELLA TYPHIMURIUM; STAPHYLOCOCCUS AUREUS; DRUG EFFECTS; DRUG POTENTIATION; GRAM NEGATIVE BACTERIUM; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; POSIBACTERIA;

ANTI-BACTERIAL AGENTS; BACTERIOCINS; DRUG SYNERGISM; GRAM-NEGATIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; POLYMYXINS;

EID: 84884561705     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-13-212     Document Type: Article

References (47)

1. Bacteriocins-a viable alternative to antibiotics? Cotter PD, Ross RP, Hill C, Nat Rev Microbiol 2013 11 95 105 23268227
2. Discovery of medically significant lantibiotics. Piper C, Cotter PD, Ross RP, Hill C, Curr Drug Discov Technol 2009 6 1 18 10.2174/157016309787581075 19275538
3. Biosynthesis and mode of action of lantibiotics. Chatterjee C, Paul M, Xie L, van der Donk WA, Chem Rev 2005 105 633 684 10.1021/cr030105v 15700960 (Pubitemid 40356090)
4. Lantibiotics: mode of action, biosynthesis and bioengineering. Bierbaum G, Sahl HG, Curr Pharm Biotechnol 2009 10 2 18 10.2174/138920109787048616 19149587
5. Lacticin 3147-biosynthesis, molecular analysis, immunity, bioengineering and applications. Suda S, Cotter PD, Hill C, Ross RP, Curr Protein Pept Sci 2012 13 193 204 10.2174/138920312800785021 21827422
6. Sequential actions of the two component peptides of the lantibiotic lacticin 3147 explain its antimicrobial activity at nanomolar concentrations. Morgan SM, O'Connor PM, Cotter PD, Ross RP, Hill C, Antimicrob Agents Chemother 2005 49 2606 2611 10.1128/AAC.49.7.2606-2611.2005 15980326 (Pubitemid 40917568)
7. The mode of action of the lantibiotic lacticin 3147-a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. Wiedemann I, Bottiger T, Bonelli RR, Wiese A, Hagge SO, Gutsmann T, Seydel U, Deegan L, Hill C, Ross P, Sahl HG, Mol Microbiol 2006 61 285 296 10.1111/j.1365-2958.2006.05223.x 16771847 (Pubitemid 44356563)
8. Comparison of the activities of the lantibiotics nisin and lacticin 3147 against clinically significant mycobacteria. Carroll J, Draper LA, O'Connor PM, Coffey A, Hill C, Ross RP, Cotter PD, O'Mahony J, Int J Antimicrob Agents 2010 36 2 132 136 10.1016/j.ijantimicag.2010.03.029 20547041
9. Antimicrobial activity of lacticin 3,147 against clinical Clostridium difficile strains. Rea MC, Clayton E, O'Connor PM, Shanahan F, Kiely B, Ross RP, Hill C, J Med Microbiol 2007 56 940 946 10.1099/jmm.0.47085-0 17577060 (Pubitemid 47047488)
10. Comparison of the potency of the lipid II targeting antimicrobials nisin, lacticin 3147 and vancomycin against Gram-positive bacteria. Iancu C, Grainger A, Field D, Cotter P, Hill C, Ross RP, Probiotics Antimicrob Proteins 2012 4 108 115 10.1007/s12602-012-9095-x
11. Polymyxin and related peptide antibiotics. Storm DR, Rosenthal KS, Swanson PE, Annu Rev Biochem 1977 46 723 763 10.1146/annurev.bi.46.070177.003451 197881 (Pubitemid 8252143)
12. The use of colimycin ear drops. Ohzawa R, Jibiinkoka 1965 37 585 590 5890692
13. Clinical use of colimycin F otic solution. Nakajima S, Jibiinkoka 1965 37 693 697 5890449
14. Structure-activity relationships of polymyxin antibiotics. Velkov T, Thompson PE, Nation RL, Li J, J Med Chem 2010 53 1898 1916 10.1021/jm900999h 19874036
15. Agents that increase the permeability of the outer membrane. Vaara M, Microbiol Rev 1992 56 395 411 1406489
16. Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Morrison DC, Jacobs DM, Immunochemistry 1976 13 813 818 10.1016/0019-2791(76)90181-6 187544
17. Titration calorimetric studies to elucidate the specificity of the interactions of polymyxin B with lipopolysaccharides and lipid A. Srimal S, Surolia N, Balasubramanian S, Surolia A, Biochem J 1996 315 Pt 2 679 686 8615847
18. The bacterial outer membrane as a drug barrier. Hancock RE, Trends Microbiol 1997 5 37 42 10.1016/S0966-842X(97)81773-8 9025234 (Pubitemid 27077171)
19. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Falagas ME, Kasiakou SK, Crit Care 2006 10 27 10.1186/cc3995 16507149 (Pubitemid 47079794)
20. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant Gram-negative bacteria. Evans ME, Feola DJ, Rapp RP, Ann Pharmacother 1999 33 960 967 10.1345/aph.18426 10492501 (Pubitemid 29420995)
21. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Falagas ME, Kasiakou SK, Clin Infect Dis 2005 40 1333 1341 10.1086/429323 15825037 (Pubitemid 40570245)
22. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. Zavascki AP, Goldani LZ, Li J, Nation RL, J Antimicrob Chemother 2007 60 1206 1215 10.1093/jac/dkm357 17878146 (Pubitemid 350168315)
23. Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms. Yuan Z, Tam VH, Expert Opin Investig Drugs 2008 17 661 668 10.1517/13543784.17.5.661 18447592 (Pubitemid 351843610)
24. Synergistic effects of miconazole and polymyxin B on microbial pathogens. Pietschmann S, Hoffmann K, Voget M, Pison U, Vet Res Commun 2009 33 489 505 10.1007/s11259-008-9194-z 19085068
25. In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa. Giamarellos-Bourboulis EJ, Sambatakou H, Galani I, Giamarellou H, J Chemother 2003 15 235 238 12868548 (Pubitemid 36819310)
26. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Giamarellos-Bourboulis EJ, Xirouchaki E, Giamarellou H, Diagn Microbiol Infect Dis 2001 40 117 120 10.1016/S0732-8893(01)00258-9 11502379 (Pubitemid 32735549)
27. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME, Antimicrob Agents Chemother 2005 49 3136 3146 10.1128/AAC.49.8.3136-3146.2005 16048915 (Pubitemid 41060551)
28. Eradication of early Pseudomonas aeruginosa infection. Hoiby N, Frederiksen B, Pressler T, J Cyst Fibros 2005 4 Suppl 2 49 54 16023416 (Pubitemid 41131329)
29. In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Vidaillac C, Benichou L, Duval RE, Antimicrob Agents Chemother 2012 56 4856 4861 10.1128/AAC.05996-11 22751540
30. Colistin: new lessons on an old antibiotic. Yahav D, Farbman L, Leibovici L, Paul M, Clin Microbiol Infect 2012 18 18 29 10.1111/j.1469-0691.2011.03734.x 22168320
31. Nisin A and polymyxin B as synergistic inhibitors of Gram-positive and Gram-negative bacteria. Naghmouchi K, Drider D, Baah J, Teather R, Probiotics Antimicrob Proteins 2010 2 98 103 10.1007/s12602-009-9033-8
32. Antibacterial activity of class I and IIa bacteriocins combined with polymyxin E against resistant variants of Listeria monocytogenes and Escherichia coli. Naghmouchi K, Belguesmia Y, Baah J, Teather R, Drider D, Res Microbiol 2011 162 99 107 10.1016/j.resmic.2010.09.014 20868743
33. In vitro activity of cationic peptides alone and in combination with clinically used antimicrobial agents against Pseudomonas aeruginosa. Giacometti A, Cirioni O, Barchiesi F, Fortuna M, Scalise G, J Antimicrob Chemother 1999 44 641 645 10.1093/jac/44.5.641 10552980 (Pubitemid 29532842)
34. Efficacy of organic acids, bacteriocins, and the lactoperoxidase system in inhibiting the growth of Cronobacter spp. in rehydrated infant formula. Oshima S, Rea MC, Lothe S, Morgan S, Begley M, O'Connor PM, Fitzsimmons A, Kamikado H, Walton R, Ross RP, Hill C, J Food Prot 2012 75 1734 1742 10.4315/0362-028X.JFP-12-066 23043820
35. A comparison of the activities of lacticin 3147 and nisin against drug-resistant Staphylococcus aureus and Enterococcus species. Piper C, Draper LA, Cotter PD, Ross RP, Hill C, J Antimicrob Chemother 2009 64 546 551 10.1093/jac/dkp221 19561147
36. Synergistic effect between colistin and bacteriocins in controlling Gram-negative pathogens and their potential to reduce antibiotic toxicity in mammalian epithelial cells. Naghmouchi K, Baah J, Hober D, Jouy E, Rubrecht C, Sane F, Drider D, Antimicrob Agents Chemother 2013 57 2719 2725 10.1128/AAC.02328-12 23571533
37. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. Gales AC, Reis AO, Jones RN, J Clin Microbiol 2001 39 183 190 10.1128/JCM.39.1.183-190.2001 11136768 (Pubitemid 32059588)
38. Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Hermsen ED, Sullivan CJ, Rotschafer JC, Infect Dis Clin North Am 2003 17 545 562 10.1016/S0891-5520(03)00058-8 14711076 (Pubitemid 38029152)
39. Efficacy of a teat dip containing the bacteriocin lacticin 3147 to eliminate Gram-positive pathogens associated with bovine mastitis. Klostermann K, Crispie F, Flynn J, Meaney WJ, Ross RP, Hill C, J Dairy Res 2010 77 231 238 10.1017/S0022029909990239 19785910
40. Evaluation of lacticin 3147 and a teat seal containing this bacteriocin for inhibition of mastitis pathogens. Ryan MP, Meaney WJ, Ross RP, Hill C, Appl Environ Microbiol 1998 64 2287 2290 9603853 (Pubitemid 28252803)
41. Mammary pathogenic Escherichia coli. Shpigel NY, Elazar S, Rosenshine I, Curr Opin Microbiol 2008 11 60 65 10.1016/j.mib.2008.01.004 18291708
42. The «other» Gram-negative bacteria in mastitis: Klebsiella, Serratia, and more. Schukken Y, Chuff M, Moroni P, Gurjar A, Santisteban C, Welcome F, Zadoks R, Vet Clin North Am Food Anim Pract 2012 28 239 256 10.1016/j.cvfa.2012.04.001 22664206
43. A practical look at environmental mastitis. Hogan JS, Smith KL, Comp Cont Educ Pract 1987 9 341 F346
44. Roles of Antibodies and Complement in Phagocytic Killing of Enterococci. Arduino RC, Murray BE, Rakita RM, Infection and Immunity 1994 62 987 993 8112874 (Pubitemid 24065586)
45. Overproduction of wild-type and bioengineered derivatives of the lantibiotic lacticin 3147. Cotter PD, Draper LA, Lawton EM, McAuliffe O, Hill C, Ross RP, Appl Environ Microbiol 2006 72 4492 4496 10.1128/AEM.02543-05 16751576 (Pubitemid 43894930)
46. The ABC transporter AnrAB contributes to the innate resistance of Listeria monocytogenes to nisin, bacitracin, and various beta-lactam antibiotics. Collins B, Curtis N, Cotter PD, Hill C, Ross RP, Antimicrob Agents Chemother 2010 54 4416 4423 10.1128/AAC.00503-10 20643901
47. Mecillinam - an amidino penicillin which acts synergistically with other beta-lactam compounds. Neu HC, J Antimicrob Chemother 1977 3 Suppl B 43 52 10.1093/jac/3.suppl-B.43 413824 (Pubitemid 8145188)